TAI'AN, China, March 4, 2011 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (Nasdaq: CBPO), one of the leading plasma-based biopharmaceutical companies in the People's Republic of China, today announced that Mr. Stanley Lau, President, Dr. Vincent Yi-Wu Xie, Director of Research & Development, and Mr. Ming Yin, Vice President of Finance, will present at the Cowen and Company Healthcare Conference at 2:00 p.m. on March 7, 2011 in the Regis room on the third floor of the Boston Marriott Copley Place hotel, in Boston, Massachusetts. The company will also attend smaller meetings during the conference.
For more information about the conference, please contact your Cowen and Company representative or visit http://www.cowen.com/Conferences.html.
About China Biologic Products, Inc.
China Biologic Products, Inc., through its indirect majority-owned subsidiaries, Shandong Taibang Biological Products Co., Ltd. and Guiyang Dalin Biologic Technologies Co., Ltd., and its equity investment in Xi'an Huitian Blood Products Co., Ltd., is one of the leading plasma-based biopharmaceutical companies in China. The company is a fully integrated biologic products company with plasma collection, production and manufacturing, research and development, and commercial operations. The company's plasma-based biopharmaceutical products are irreplaceable during medical emergencies and are used for the prevention and treatment of various diseases. The company sells its products to hospitals and other healthcare facilities in China. For more information, please visit the company's website at http://www.chinabiologic.com.
Mr. Y. Tristan Kuo
Chief Financial Officer
China Biologic Products, Inc.
Telephone: +86-538-6202206 in China
SOURCE China Biologic Products, Inc.